Navigation Links
Pharmasset Joins Russell 3000 Index
Date:7/1/2008

PRINCETON, N.J., July 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) joined the broad-market Russell 3000(R) Index when Russell Investments reconstituted its equity indexes on June 27.

Pharmasset's membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000(R) Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers for index funds and as benchmarks for both passive and active investment strategies currently applied to $4.4 trillion in assets.

"We are pleased to be included in these indexes only one year after our stock became publicly traded," stated Kurt Leutzinger, Pharmasset's Chief Financial Officer. "We feel fortunate that our stock price has grown 117% since the IPO in an otherwise difficult market."

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
2. Pharmasset Selected to Join the NASDAQ Biotechnology Index
3. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
4. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
5. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
6. Pharmasset Receives $10 Million of Working Capital
7. Pharmasset Appoints Herbert J. Conrad as a Director
8. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
9. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
10. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
11. Pharmasset Reports Fiscal Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... temper tantrums lately? Or an adolescent episode of hormone-clouded ... a bit of flagging memory? , ,Given that organizations ... another, it's easy to begin thinking about organizations as ... they age. It's even understandable to want a model ...
... ,Jia Hu of China - Source: Getty Images The ... every four years. They're held every year. Though this is ... year as the pervasive growth of the industry becomes part ... run every four years and last two weeks, the biotech ...
... MADISON, Wis. - Ownership and accountability is the way ... 448-bed community hospital in Madison that provides medical care ... living facility, laboratories and a home health care service. ... Methodist Hospital in 1987, Meriter includes more than 430 ...
Cached Biology Technology:Aging IT 2Aging IT 3The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4
(Date:7/9/2014)... are less fit in terms of cardiorespiratory capacity, ... Moreover, southern adolescents are more obese and present ... those from the centre-north of Europe. , These ... ambitious study conducted by scientists from the University ... with 25 other European research groups. The study ...
(Date:7/9/2014)... if they are used in the right ways. ... Women,s Hospital and coauthors analyzed six use cases ... triage; decompensation (when a patient,s condition worsens); adverse ... multiple organ systems. They suspect that cost-savings benefits ... with all six scenarios will be significant. The ...
(Date:7/8/2014)... run" or as a well-deserved break, and you,ll eat less afterward. ... you,ll later eat more dessert and snacks to reward yourself. , ... involved two studies where adults were led on a 2 km ... going to be an exercise walk or a scenic walk. ... were then given lunch. Those who believed they had been ...
Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
... today for the HudsonAlpha- Science 2014 Conference on ... HudsonAlpha biotechnology campus in Huntsville, Ala. The ... of this emerging scientific field. ImmunoGenomics sits at ... the use of DNA sequencing to improve disease diagnosis ...
... an oil spill, and images of fouled beaches and ... visible effects as well. For instance, even low levels ... fish embryos and larvae, reducing the likelihood that those ... for some time, but the underlying mechanism has remained ...
... by memory deficits. Basel scientists have now identified a ... is important for human brain activity, memory and the development ... online edition of the US journal Neuron . ... a telephone number - is a fundamental function of the ...
Cached Biology News:Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 2Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 3Scientists discover the mechanism of heart failure in fish exposed to oil spills 2Scientists discover the mechanism of heart failure in fish exposed to oil spills 3How memory and schizophrenia are connected 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: